Deborah M Siegal

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9003231/deborah-m-siegal-publications-by-year.pdf

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

5,467
citations

h-index

73
g-index

7,225
ext. papers

9.2
avg, IF

L-index

#	Paper	IF	Citations
98	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 227-236	27.4	18
97	Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study <i>Leukemia Research</i> , 2022 , 113, 106788	2.7	
96	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism <i>Blood Reviews</i> , 2022 , 100970	11.1	3
95	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on post-discharge thromboprophylaxis. <i>Blood Advances</i> , 2021 ,	7.8	14
94	A Population Cohort Study to Evaluate the Risk of Ischemic Stroke Among Individuals with a New Diagnosis of Cancer Compared to Matched Cancer-Free Controls: Impact of Prior Stroke History. <i>Blood</i> , 2021 , 138, 175-175	2.2	
93	Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM-Line): A two-center open-label pilot randomized controlled trial. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12517	5.1	2
92	Are the correct outcomes being measured in studies of oral anticoagulants? A systematic survey. <i>Thrombosis Research</i> , 2021 , 201, 30-49	8.2	O
91	Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2383-2393	15.4	O
90	Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2504-2513	15.4	O
89	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021 , 117, 576-584	9.9	10
88	Thinking Outside the Inbox: Use of Slack in Clinical Groups as a Collaborative Team Communication Platform. <i>AEM Education and Training</i> , 2021 , 5, 121-129	2.2	5
87	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021 , 126, 163-171	5.4	9
86	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021 , 126, 172	2- 1 80	3
85	Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health-care providers. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 153-160	15.4	4
84	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 30-40	15.4	1
83	Ciraparantag: the next anticoagulant airbag?. Blood, 2021 , 137, 10-11	2.2	0
82	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. <i>Cmaj</i> , 2021 , 193, E304-E309	3.5	5

(2020-2021)

81	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1097-1106	7	5
80	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. <i>Blood Advances</i> , 2021 , 5, 872-888	7.8	161
79	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 790-802	59.2	203
78	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021 , 385, 777-789	59.2	227
77	Incidence of stroke in the first year after diagnosis of cancer-A protocol for systematic review and meta-analysis. <i>PLoS ONE</i> , 2021 , 16, e0256825	3.7	O
76	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. <i>Blood Advances</i> , 2021 , 5, 3951-3959	7.8	12
75	Barriers and facilitators for optimizing oral anticoagulant management: Perspectives of patients, caregivers, and providers. <i>PLoS ONE</i> , 2021 , 16, e0257798	3.7	О
74	Media portrayals of pulmonary embolism. <i>Thrombosis Research</i> , 2021 , 206, 52-54	8.2	
73	Intravenous iron therapy for patients with preoperative iron deficiency or anaemia undergoing cardiac surgery reduces blood transfusions: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020 , 31, 141-151	1.8	5
72	Characterizing Frailty in Myeloproliferative Neoplasms: Baseline Results from the Orchid Study. <i>Blood</i> , 2020 , 136, 9-10	2.2	O
71	Detection of Right Ventricular Dysfunction in Acute Pulmonary Embolism By CT Scan: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2020 , 136, 25-26	2.2	
70	The Use of Transthoracic Echocardiograms in Hospitalized Adult Patients with Acute Pulmonary Embolism. <i>Blood</i> , 2020 , 136, 43-43	2.2	1
69	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. <i>Blood Advances</i> , 2020 , 4, 6259-6273	7.8	5
68	Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk. <i>Heart</i> , 2020 , 106, 845-851	5.1	1
67	Blood loss from laboratory testing, anemia, and red blood cell transfusion in the intensive care unit: a retrospective study. <i>Transfusion</i> , 2020 , 60, 256-261	2.9	9
66	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 594-622	15.1	69
65	Prothrombin complex concentrates for DOAC-associated bleeding, global coagulation assays, and assessments of clinical hemostasis: How to gauge the impact?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 677-679	5.1	0
64	Iron deficiency following bariatric surgery: a retrospective cohort study. <i>Blood Advances</i> , 2020 , 4, 3639	-3 6 . \$ 7	11

63	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. <i>Journal of Intensive Care Medicine</i> , 2020 , 35, 1074-1079	3.3	4
62	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding. <i>Thrombosis Research</i> , 2019 , 180, 86	8.2	
61	Refractory urticaria and the importance of diagnosing Schnitzler's syndrome. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	3
60	Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic acid: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019 , 179, 81-86	8.2	29
59	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019 , 380, 1326-1335	59.2	431
58	Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. <i>Lancet, The</i> , 2019 , 394, 1022-1029	40	69
57	Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic	15.4	29
56	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2019 , 45, 793-801	5.3	8
55	Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pragmatic Stepped Wedge Cluster Randomized Trial. <i>Blood</i> , 2019 , 134, 3685-3685	2.2	5
54	What we have learned about direct oral anticoagulant reversal. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 198-203	3.1	3
53	Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2019 , 175, 102-109	8.2	32
52	Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 204-208	3.1	2
51	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019 , 15, 395-404	1.3	2
50	579 The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, S332-S333	0.7	2
49	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19
48	Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 251-265	5.1	23
47	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018 , 163, 19-21	8.2	5
46	Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. <i>Thrombosis Research</i> , 2018 , 167, 6-8	8.2	1

(2015-2018)

45	Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. Journal of Thrombosis and Haemostasis, 2018 , 16, 2008-2015	15.4	9
44	The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. <i>Leukemia Research</i> , 2018 , 70, 62-66	2.7	2
43	Blood Loss Due to Laboratory Testing in Critical Care Patients: A Retrospective Cohort Study. <i>Blood</i> , 2018 , 132, 4885-4885	2.2	
42	Small-Volume Tubes to Reduce Transufusion (STRATUS): A Pilot Study. <i>Blood</i> , 2018 , 132, 825-825	2.2	1
41	Specific antidotes for bleeding associated with direct oral anticoagulants. <i>BMJ, The</i> , 2017 , 357, j2216	5.9	15
40	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. <i>Blood Advances</i> , 2017 , 1, 1827-1838	7.8	35
39	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017 , 157, 165-166	8.2	6
38	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 3042-3067	15.1	228
37	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017 , 160, 97-104	8.2	11
36	Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia: A Systematic Review. <i>Annals of Internal Medicine</i> , 2017 , 167, 170-180	8	31
35	Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. <i>Chest</i> , 2017 , 151, 127-138	5.3	185
34	Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. <i>Blood Advances</i> , 2017 , 1, 772-778	7.8	64
33	Occult Amebic Liver Abscess as Cause of Extensive Inferior Vena Cava and Hepatic Vein Thrombosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017 , 97, 1214-1217	3.2	5
32	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016 , 375, 1131-41	59.2	580
31	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 879-890	7	95
30	The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. <i>Blood</i> , 2016 , 128, 138-40	2.2	146
29	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 231-9	5.1	22
28	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015 , 373, 2413-24	59.2	754

27	Plasma versus prothrombin complex concentrate for warfarin-associated major bleeding: a systematic review. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 448-53	3.1	4
26	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 117-24	3.1	41
25	Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 395-402	5.1	60
24	Monitoring and reversal of direct oral anticoagulants. <i>Hematology American Society of Hematology Education Program</i> , 2015 , 2015, 117-124	3.1	9
23	Non-Specific Hemostatic Agents (PCC, aPCC, rVIIa) for Reversal of Direct Oral Anticoagulant Effect in Patients with Major Bleeding Complications: A Retrospective Review. <i>Blood</i> , 2015 , 126, 1137-1137	2.2	O
22	Efficacy and Safety of Weight-Adjusted Extended Duration Tinzaparin for Prevention of Post-Operative Venous Thromboembolism after Bariatric Surgery. <i>Blood</i> , 2015 , 126, 1130-1130	2.2	О
21	Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. Journal of the American College of Cardiology, 2014 , 64, 1128-39	15.1	357
20	Reversal of target-specific oral anticoagulants. <i>Drug Discovery Today</i> , 2014 , 19, 1465-70	8.8	30
19	How I treat target-specific oral anticoagulant-associated bleeding. <i>Blood</i> , 2014 , 123, 1152-8	2.2	93
18	What is the effect of rivaroxaban on routine coagulation tests?. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 334-6	3.1	4
17	Thrombopoietin receptor agonists in primary immune thrombocytopenia. <i>Seminars in Hematology</i> , 2013 , 50 Suppl 1, S18-21	4	29
16	Acute management of bleeding in patients on novel oral anticoagulants. <i>European Heart Journal</i> , 2013 , 34, 489-498b	9.5	138
15	Reversal of novel oral anticoagulants in patients with major bleeding. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 391-8	5.1	71
14	Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. <i>Circulation</i> , 2012 , 126, 1630-9	16.7	322
13	Acute hepatic necrosis and ischemic limb necrosis. New England Journal of Medicine, 2012, 367, 879-81	59.2	16
12	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , 2011 , 118, 545-545	2.2	1
11	Use of kidney function end points in kidney transplant trials: a systematic review. <i>American Journal of Kidney Diseases</i> , 2010 , 56, 1140-57	<i>7</i> ⋅4	19
10	Type II bidirectional ventricular tachycardia as a mechanism of termination of sustained ventricular tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 345-6	2.7	7

LIST OF PUBLICATIONS

9	Complete heart block following intentional carbamate ingestion. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e288-90	3.8	6	
8	A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. <i>Clinical Infectious Diseases</i> , 2008 , 47, 885	-9 ¹ 2 ^{1.6}	60	
7	A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1576-82	11.6	66	
6	Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1369-79	4.7	125	
5	A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. <i>American Journal of Transplantation</i> , 2005 , 5, 1462-8	8.7	80	
4	Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. <i>American Journal of Transplantation</i> , 2005 , 5, 2031-6	8.7	211	
3	A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1154-7	7	40	
2	Brain vesicular acetylcholine transporter in human users of drugs of abuse. <i>Synapse</i> , 2004 , 52, 223-32	2.4	22	
1	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with Blood Advances,	7.8	4	